Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

THEMIS MEDICARE LTD. - 530199 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 In a landmark development for the treatment of COVID-19, Themis Medicare Ltd. (Themis), a Pharmaceutical company headquartered in Mumbai with a legacy of over 50 years of making new treatment options available, announced the approval of its antiviral drug VIRALEX(r) by the Drug Controller General of India (DCGI). As per the results of a double-blind randomized controlled trials (RCT), the drug helps in early relief of the clinical symptoms in mild to moderate COVID-19 patients.
21-03-2022
Bigul

THEMIS MEDICARE LTD. - 530199 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 Subject: Intimation of Investor/Analyst meet Pursuant to regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Listing Regulations') read with part A of Schedule III of the Listing Regulations, we wish to inform that the management of the Company had a call with Analysts/Investors on Monday, 7th March 2022; the details of the same are given below: Sr. no. Name Venue 1 Faering Capital Zoom Call Pursuant to regulation 46(2) of the Listing Regulations, aforesaid information shall be disclosed on the website of the company viz. www.themismedicare.com This is for your information and record.
07-03-2022
Bigul

THEMIS MEDICARE LTD. - 530199 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Listing Regulations') read with part A of Schedule III of the Listing Regulations, we wish to inform that the management of the Company will have a call with Analysts/Investors on Monday, 7th March 2022; the details of the same are given below: Sr. no. Name Venue 1 Faering Capital Zoom Call Note: The schedule of the aforesaid meetings is subject to change. The changes may happen due to exigencies on the part of Fund / Broking House / Company. Pursuant to regulation 46(2) of the Listing Regulations, aforesaid information shall be disclosed on the website of the company viz. www.themismedicare.com
04-03-2022

Themis Medicare Consolidated December 2021 Net Sales at Rs 94.92 crore, up 44.88% Y-o-Y

 NULL
04-03-2022
Bigul

THEMIS MEDICARE LTD. - 530199 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 In a landmark development for Themis Medicare Ltd (Themis), the Company has received approval for its immunomodulatory antiviral drug VIRALEX(r) (Generic name: Inosine Pranobex) for treatment of COVID-19, from Drug Controller General of India (DCGI) vide CDSCO letter no ND/CT21/FF/2021/25932 dated 02 Mar 2022. The drug regulatory authority granted permission to manufacture and market this new drug for restricted emergency use as add on therapy for treatment of mild and moderate COVID-19, under NDCT Rules 2019 based on evaluation in consultation with the Subject Expert Committee (SEC) as part of accelerated approval process considering the emergency situation and unmet medical need in light of COVID-19 outbreak in the country. VIRALEX(r) would be available on prescription.
03-03-2022
Bigul

THEMIS MEDICARE LTD. - 530199 - Announcement Under Regulation 30(LODR)-Update(Business Update)

 In a landmark development for Themis Medicare Ltd (Themis), the Company has received approval for its immunomodulatory antiviral drug VIRALEX(r) (Generic name: Inosine Pranobex) for treatment of COVID-19, from Drug Controller General of India (DCGI) vide CDSCO letter no ND/CT21/FF/2021/25932 dated 02 Mar 2022. The drug regulatory authority granted permission to manufacture and market this new drug for restricted emergency use as add on therapy for treatment of mild and moderate COVID-19, under NDCT Rules 2019 based on evaluation in consultation with the Subject Expert Committee (SEC) as part of accelerated approval process considering the emergency situation and unmet medical need in light of COVID-19 outbreak in the country. VIRALEX(r) would be available on prescription.
03-03-2022
Bigul

THEMIS MEDICARE LTD. - 530199 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

 This is to inform that the company has allotted 730 (seven hundred and thirty) Equity shares of Rs.10/-(Rupees Ten only) each on February 28, 2022 to those grantees who had exercised their option under the Company's Employee Stock Option Scheme. The said shares will rank pari-passu with the existing shares of the Company in all respect. Please take the above on record and upload this announcement on the website of the Exchange.
28-02-2022
Bigul

THEMIS MEDICARE LTD. - 530199 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Pursuant to Regulations 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Media Release issued by the Company on its financial results for the third quarter and nine months ended 31st December 2021. This is for your information and records.
15-02-2022
Bigul

THEMIS MEDICARE LTD. - 530199 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 In terms of Regulations 47 of SEBI(LODR) Regulations, 2015 the company has published the Un-Audited Financial Results for the quarter and Nine months ended 31st December,2021 in ''Indian Express'' (English) edition and in Financials Express'' (Gujarati) edition on Saturday, 12th February, 2022. Further, in pursuance of Regulation 30 read with Schedule III (A) (12) please find enclosed the copy of Newspaper articles as published in the above mentioned newspapers. Kindly take the same on record and acknowledge receipt.
14-02-2022
Bigul

THEMIS MEDICARE LTD. - 530199 - Results-Financial Results For December 31, 2021(Quarterly)

 The Board of Directors at its meeting held today, considered and approved the following matters: 1. Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine months ended 31st December 2021. A copy of Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine months ended 31st December, 2021 is enclosed herewith. 2. Appointed M/s. SAV & Associates LLP as Secretarial Auditor for the financial year 2021-22 for the purpose of conducting Secretarial Audit. 3. A Risk Management Committee of the Company has been constituted. 4. The Board has formulated a Dividend Distribution Policy. 5. The Board of Directors took note of the following: a) The tenure of appointment of Mrs. Jayshree D Patel, Whole Time Director ends on 27th March, 2022 b) Mrs. Jayshre D. Patel will not be seeking reappointment. c) Mrs. Jayshree D. Patel will be stepping down as Director w.e.f. closure of business hours on 27th March,2022.
11-02-2022
Next Page
Close

Let's Open Free Demat Account